Indevus Pharmaceuticals and Valera Pharmaceuticals have entered into a definitive agreement under which Indevus will acquire Valera in a transaction valued at $120 million plus contingent payments based on future product milestones. Valera focuses on the development and commercialization of urology and endocrinology products. The company markets Vantas for advanced prostate cancer and has multiple products in clinical development including Supprelin-LA for central precocious puberty for whi...